CN114040978B - 用于治疗cd33阳性恶性肿瘤的经cd33靶向性嵌合抗原受体修饰的t细胞 - Google Patents

用于治疗cd33阳性恶性肿瘤的经cd33靶向性嵌合抗原受体修饰的t细胞

Info

Publication number
CN114040978B
CN114040978B CN202080047912.8A CN202080047912A CN114040978B CN 114040978 B CN114040978 B CN 114040978B CN 202080047912 A CN202080047912 A CN 202080047912A CN 114040978 B CN114040978 B CN 114040978B
Authority
CN
China
Prior art keywords
gly
leu
ser
pro
thr
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Active
Application number
CN202080047912.8A
Other languages
English (en)
Chinese (zh)
Other versions
CN114040978A (zh
Inventor
T.薛
D.A.霍恩
L.E.布德
S.福曼
M.M.德尔里尔
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
City of Hope
Original Assignee
City of Hope
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by City of Hope filed Critical City of Hope
Publication of CN114040978A publication Critical patent/CN114040978A/zh
Application granted granted Critical
Publication of CN114040978B publication Critical patent/CN114040978B/zh
Active legal-status Critical Current
Anticipated expiration legal-status Critical

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
    • C12N15/62—DNA sequences coding for fusion proteins
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
    • A61K35/12—Materials from mammals; Compositions comprising non-specified tissues or cells; Compositions comprising non-embryonic stem cells; Genetically modified cells
    • A61K35/14—Blood; Artificial blood
    • A61K35/17—Lymphocytes; B-cells; T-cells; Natural killer cells; Interferon-activated or cytokine-activated lymphocytes
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A61P35/02—Antineoplastic agents specific for leukemia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/705—Receptors; Cell surface antigens; Cell surface determinants
    • C07K14/70503—Immunoglobulin superfamily
    • C07K14/7051—T-cell receptor (TcR)-CD3 complex
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2803—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the immunoglobulin superfamily
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • C12N15/79—Vectors or expression systems specially adapted for eukaryotic hosts
    • C12N15/85—Vectors or expression systems specially adapted for eukaryotic hosts for animal cells
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N5/00—Undifferentiated human, animal or plant cells, e.g. cell lines; Tissues; Cultivation or maintenance thereof; Culture media therefor
    • C12N5/06—Animal cells or tissues; Human cells or tissues
    • C12N5/0602—Vertebrate cells
    • C12N5/0634—Cells from the blood or the immune system
    • C12N5/0636—T lymphocytes
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/02—Fusion polypeptide containing a localisation/targetting motif containing a signal sequence
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide
    • C07K2319/01—Fusion polypeptide containing a localisation/targetting motif
    • C07K2319/03—Fusion polypeptide containing a localisation/targetting motif containing a transmembrane segment
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N2510/00—Genetically modified cells

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Organic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Zoology (AREA)
  • General Health & Medical Sciences (AREA)
  • Molecular Biology (AREA)
  • Biotechnology (AREA)
  • Biochemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Wood Science & Technology (AREA)
  • Biophysics (AREA)
  • General Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Plant Pathology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Toxicology (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Hematology (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Oncology (AREA)
  • Virology (AREA)
  • Developmental Biology & Embryology (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
CN202080047912.8A 2019-05-31 2020-06-01 用于治疗cd33阳性恶性肿瘤的经cd33靶向性嵌合抗原受体修饰的t细胞 Active CN114040978B (zh)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201962855906P 2019-05-31 2019-05-31
US62/855,906 2019-05-31
PCT/US2020/035579 WO2020243713A2 (en) 2019-05-31 2020-06-01 Cd33 targeted chimeric antigen receptor modified t cells for treatment of cd33 positive malignancies

Publications (2)

Publication Number Publication Date
CN114040978A CN114040978A (zh) 2022-02-11
CN114040978B true CN114040978B (zh) 2025-10-17

Family

ID=71842756

Family Applications (1)

Application Number Title Priority Date Filing Date
CN202080047912.8A Active CN114040978B (zh) 2019-05-31 2020-06-01 用于治疗cd33阳性恶性肿瘤的经cd33靶向性嵌合抗原受体修饰的t细胞

Country Status (6)

Country Link
US (1) US12565658B2 (https=)
EP (1) EP3976794A2 (https=)
JP (1) JP7631234B2 (https=)
CN (1) CN114040978B (https=)
CA (1) CA3142159A1 (https=)
WO (1) WO2020243713A2 (https=)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
TW202110873A (zh) 2019-04-30 2021-03-16 美商聖堤生物科技股份有限公司 嵌合受體及其使用方法

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104877032A (zh) * 2015-06-26 2015-09-02 中国医学科学院血液病医院（血液学研究所） Cd33特异性嵌合抗原受体及其应用
CN107267619A (zh) * 2017-07-04 2017-10-20 武汉波睿达生物科技有限公司 一种检测靶向cd33的cart细胞中car表达的荧光定量试剂盒

Family Cites Families (8)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN106795221B (zh) 2014-04-03 2022-06-07 塞勒克提斯公司 用于癌症免疫治疗的cd33特异性嵌合抗原受体
CN105384823A (zh) * 2014-08-26 2016-03-09 中国人民解放军总医院 嵌合抗原受体及其基因和重组表达载体、工程化cd33靶向性的nkt细胞及其应用
CA2992989A1 (en) 2015-07-21 2017-01-26 City Of Hope T cells for expression of chimeric antigen receptors and other receptors
MX389194B (es) * 2015-10-06 2025-03-20 Univ Minnesota Compuestos terapéuticos y métodos.
EP4613776A3 (en) 2016-10-21 2025-11-26 Altor BioScience Corporation Multimeric il-15-based molecules
CN110650975B (zh) * 2017-05-15 2024-04-05 美国卫生和人力服务部 双顺反子嵌合抗原受体及其用途
CN107353343A (zh) * 2017-07-04 2017-11-17 武汉波睿达生物科技有限公司 一种靶向表达cd33表面抗原的细胞的嵌合抗原受体
EA202092044A1 (ru) 2018-03-14 2021-03-03 Дзе Юнайтед Стейтс Оф Америка, Эз Репрезентед Бай Дзе Секретари, Департмент Оф Хелс Энд Хьюман Сёрвисез Химерные рецепторы антигена против cd33 и их применения

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN104877032A (zh) * 2015-06-26 2015-09-02 中国医学科学院血液病医院（血液学研究所） Cd33特异性嵌合抗原受体及其应用
CN107267619A (zh) * 2017-07-04 2017-10-20 武汉波睿达生物科技有限公司 一种检测靶向cd33的cart细胞中car表达的荧光定量试剂盒

Also Published As

Publication number Publication date
JP7631234B2 (ja) 2025-02-18
WO2020243713A3 (en) 2021-01-07
WO2020243713A2 (en) 2020-12-03
CN114040978A (zh) 2022-02-11
US12565658B2 (en) 2026-03-03
CA3142159A1 (en) 2020-12-03
JP2022534962A (ja) 2022-08-04
US20220213489A1 (en) 2022-07-07
EP3976794A2 (en) 2022-04-06

Similar Documents

Publication Publication Date Title
JP7836847B2 (ja) 二重特異性キメラ抗原受容体およびその治療的使用
JP7527419B2 (ja) ヒトドメインを有する抗ｂ細胞成熟抗原キメラ抗原受容体
US12398187B2 (en) CD19-directed chimeric antigen receptors and uses thereof in immunotherapy
CN107074957B (zh) 在Fc间隔物区中具有突变的嵌合抗原受体(CAR)及其使用方法
US20210363245A1 (en) Bicistronic chimeric antigen receptors targeting cd19 and cd20 and their uses
CA3059444A1 (en) Chimeric antigen receptor t cells targeting the tumor microenvironment
RS66502B1 (sr) Bispecifični ili-kapijski himerni antigenski receptor koji reaguje na cd19 i cd20
CN107936120B (zh) Cd19靶向性的嵌合抗原受体及其制法和应用
CA3093810A1 (en) Il-13 receptor alpha 2 (il13ra2) chimeric antigen receptor for tumor specific t cell immunotherapy
CN111926028A (zh) Cd123特异性嵌合抗原受体重导向性t细胞及其使用方法
CN108395481B (zh) 一种靶向cd20的car的构建及其工程化t细胞的活性鉴定
CN112689642B (zh) 具有各种不同的构建物优化的t细胞抗原偶联物
US11951131B2 (en) Anti-SLAMF7 chimeric antigen receptors
KR20210129125A (ko) Baff-r/cd19 표적화된 키메라 항원 수용체-변형된 t 세포 및 그의 용도
EP4314082A1 (en) Bicistronic chimeric antigen receptors designed to reduce retroviral recombination and uses thereof
WO2023077000A1 (en) Inhibitory chimeric antigen receptor and uses thereof
Alviano et al. Fully equipped CARs to address tumor heterogeneity, enhance safety, and improve the functionality of cellular immunotherapies
EP4126016A1 (en) Augmenting antigen-negative cell death in antigen-targeted immunotherapies
CN114040978B (zh) 用于治疗cd33阳性恶性肿瘤的经cd33靶向性嵌合抗原受体修饰的t细胞
CN116600819A (zh) 靶向epcam和icam-1的双嵌合抗原受体
JP7764068B2 (ja) 機能が強化された新規キメラ抗原受容体（ｃａｒ）
WO2026030667A1 (en) Chimeric antigen receptors targeting the gamma delta t cell receptor

Legal Events

Date Code Title Description
PB01 Publication
PB01 Publication
SE01 Entry into force of request for substantive examination
SE01 Entry into force of request for substantive examination
GR01 Patent grant
GR01 Patent grant